United States: Federal Circuit's Ariosa Decision, Good Chance For Rehearing En Banc

In June of this year, the Federal Circuit panel in Ariosa Diagnostics, Inc. v. Sequenom, Inc. invalidated a patent on the grounds of patent-ineligible subject matter. 788 F.3d 1371 (Fed. Cir. 2015). While the case is one of many since the Supreme Court's Mayo decision involving patent invalidation under Section 101 of the Patent Act, Ariosa is unusual in that the asserted patent covered what most experts in the medical field consider to be a groundbreaking discovery; the very type of discovery that the patent system is intended to protect. In response to the panel's decision, and perhaps encouraged by Judge Linn's provocative concurrence, the Appellant, Sequenom, filed a petition for rehearing en banc and twelve amici curiae filed briefs in support of Sequenom's petition. On October 19, Appellees Ariosa and Natera filed responses to Sequenom's petition following an invitation from the Federal Circuit. While it is always difficult to predict whether the Federal Circuit will rehear a case en banc, the court's invitation for a response from the Appellees, Linn's concurrence, and the strong support of Sequenom's amici curiae suggest that the prospect for Ariosa is promising.

A Primer on Patentable Subject Matter

It is an undisputed doctrine of patent law that laws of nature, natural phenomena, and abstract ideas are not eligible for patent protection. And since 2010, the Supreme Court has expanded on this doctrine, issuing four landmark rulings invalidating patents under Section 101. Bilski v. Kappos, 561 U.S. 593 (2010); Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U.S. __, 132 S. Ct. 1289 (2012); Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. __, 133 S. Ct. 2107 (2013); Alice Corp. v. CLS Bank International, __ U.S. __, 134 S. Ct. 2347 (2014). In each of the four cases, the Supreme Court reinforced the doctrine of patent-ineligibility as a means of invalidating patents.

The current framework for analyzing patent eligibility is a two-part test that was established by the Supreme Court in Mayo. Mayo, 566 U.S. at 1297. First, courts must determine whether the claims are generally directed to a patent-ineligible concept (i.e., a law of nature, natural phenomenon, or abstract idea). Id. If the question is answered in the affirmative, courts must then determine whether the claims contain an "inventive concept," or "elements or a combination of elements... sufficient to ensure that the patent in practice amounts to significantly more than a patent upon the natural law itself." Id. at 1294, 1298 (citation omitted). If not, then the subject matter is patent-ineligible.

Background on Ariosa v. Sequenom

The technology in Ariosa involves non-invasive DNA-based blood tests used for prenatal diagnostics. Plaintiffs Ariosa, Natera, and DNA Diagnostics Center, and Defendant Sequenom are competitors in the prenatal diagnostics market. Sequenom and Ariosa make and sell non-invasive diagnostic tests that are used to detect fetal chromosomal abnormalities, such as Down Syndrome and Edwards Syndrome. Natera and DNA Diagnostics Center make and sell non-invasive tests used to establish paternity of a fetal sample. Prior to the technology used in Ariosa, prenatal diagnostics could only be performed by highly invasive procedures that carry the risk of fetal injury and miscarriage, such as chorionic villi sampling (CVS) and amniocentesis. The technology in Ariosa is groundbreaking in that it enables fetal diagnostics without subjecting pregnant women and their developing fetuses to the risks associated with the traditional diagnostic methods.

The asserted patent, U.S. Patent No. 6,258,540 ("the '540 patent"), covers methods of detecting cell-free fetal DNA ("cffDNA") to determine fetal characteristics, such as gender, paternity, and chromosomal abnormalities. cffDNA is DNA that originates from a pregnant woman's placenta that reflects genetic characteristics of the developing fetus. Because cffDNA circulates freely in the blood stream of pregnant women, it can be obtained from patients and used for diagnostic tests without the use of invasive procedures.

In December of 2011, Plaintiffs Ariosa and Natera filed declaratory judgment actions against Defendant Sequenom in the Northern District of California, seeking a declaration of non-infringement of the '540 patent. Sequenom filed counterclaims alleging infringement against Ariosa, Natera, and DNA Diagnostics Center. In October 2013, the Northern District granted Ariosa's motion for summary judgment of invalidity of the '540 patent under Section 101.

Federal Circuit's Decision

The Federal Circuit affirmed the district court's determination that the claimed subject matter was patent-ineligible. Applying the first step of the Mayo framework, the panel held that the claims were directed to a patent-ineligible concept. More specifically, the court found that "the claims at issue... are generally directed to detecting the presence of a naturally occurring thing or a natural phenomenon, cffDNA in maternal plasma or serum." Ariosa, 788 F.3d at 1376. Applying the second step of the Mayo framework, the panel held that the claims did not contain an inventive concept since the additional claim elements, which were DNA amplification and detection steps, were "well-understood, routine and conventional" at time of invention. Id. at 1371. In support of that finding, the panel reasoned that in order for the additional steps in the process claim to qualify as an inventive concept, it is not enough for the steps to be used in a new application; rather, the steps must themselves be new and useful. Id. at 1377. Thus, even though the steps of DNA amplification and detection had never been performed in the context of cell-free fetal DNA, such steps did not constitute an inventive concept as methods such as PCR were widely-known and practiced at the time of invention.

Regarding the preemption issue, the Federal Circuit opted not to decide the issue on its merits, instead holding that "[w]here a patent's claims are deemed only to disclose patent ineligible subject matter under the Mayo framework... preemption concerns are fully addressed and made moot." Id. at 1379.

Linn's Concurrence

Perhaps even more interesting than the panel's decision was Judge Linn's concurrence. While agreeing with the majority's application and analysis based on Mayo, Linn expressed strong disapproval at the result. He lamented: "But for the sweeping language in the Supreme Court's Mayo opinion, I see no reason, in policy or statute, why this breakthrough invention should be deemed patent ineligible." Id. at 1381 (Linn, J., concurring).

Linn's concurrence explains that the problem with the Mayo framework is that the second step of the test is overly broad and consequently invalidates otherwise valid patents. Under the Federal Circuit's interpretation of Mayo, if the "additional elements" analyzed under the second step comprise any type of "conventional activity," then such steps do not constitute "inventive concepts." But Linn suggests that in certain situations, such as where the conventional activity has never been performed in the context of the newly discovered phenomenon, such activity should constitute an inventive concept and therefore transform an otherwise patent-ineligible claim into a patentable one. Linn argues that such should have been the case in Ariosa, where "no one was amplifying and detecting paternally-inherited cffDNA using the plasma or serum of pregnant mothers." Id.

Where The Case Is Now, and Where It Is Headed

On August 13, 2015, Sequenom filed a petition for rehearing en banc, and the petition was followed by twelve supporting amici curiae briefs. The petition presents two main arguments: first, that the panel's decision is inconsistent with Supreme Court precedent, and second, that the decision greatly threatens innovation by making meritorious inventions patent-ineligible. The amici curiae similarly argue that the panel's decision should be reversed. They further explain why the decision should not stand from both legal and policy perspectives. The petition and briefs emphasize the consequences that Ariosa will have on the life sciences industry in particular, and innovation, as a whole. New diagnostics, new uses of old drugs, new vaccines, personalized medicine applications, and indeed, any invention—no matter how groundbreaking—that uses old techniques on the discovery of a natural phenomenon, will no longer be eligible for patent protection.

On October 19, Ariosa and Natera submitted responses to Sequenom's petition following an invitation from the Federal Circuit. History indicates that we can expect a decision within the next few months. While there is no way to predict whether the Federal Circuit will grant the rehearing en banc, it is clear through Linn's concurrence, Sequenom's petition, and the twelve amici curiae briefs that a decision by the Federal Circuit not to reconsider, clarify or overturn Ariosa may be an invitation for the Supreme Court's review.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
25 Sep 2018, Conference, California, United States

We're excited to introduce Women's IP Strategy, a 2-day conference that tackles both the IP, legal as well as broader career development obstacles, risks and rewards for women lawyers working in male-dominant industries.

2 Oct 2018, Webinar, California, United States

This CLE webinar will offer suggestions to litigators to help them comply with the new GDPR during e-discovery.

10 Oct 2018, Webinar, California, United States

For the past years, 3D printing has significantly revolutionized the business industry as it provides innovations and improvement to pre-existing processes.

Similar Articles
Relevancy Powered by MondaqAI
Jones Day
Davis & Gilbert
Knobbe Martens Olson & Bear
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Jones Day
Davis & Gilbert
Knobbe Martens Olson & Bear
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions